Drug intelligence / Profile preview

PVT-101

Development stage: Preclinical
Lead developer: SK Biopharmaceuticals
Modality: PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules

Overview

PVT-101 is a preclinical asset developed by Proteovant Therapeutics, a US-based clinical-stage biotech company. It is being developed for autoimmune diseases and utilizes a targeted protein degradation (TPD) platform. SK Biopharmaceuticals acquired Proteovant Therapeutics, integrating this TPD technology into its R&D efforts to target previously "undruggable" proteins, expanding its focus into oncology and biologics.

Beyond the preview

Go deeper on PVT-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PVT-101.

Explore the full profile